The potency of Trx-reduced infliximab and adalimumab relative to untreated and IAA-treated controls were determined in TNF neutralization bioassays employing the TNF-sensitive mouse fibrosarcoma WEHI-164 cell line. The gene discussed is TXN; the disease is fibrosarcoma.